Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

140.00 -42.60 (-23.33%)
Streaming Delayed Price Updated: 9:30 AM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spruce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Spruce Biosciences Announces $50.0 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
Top stock movements in today's session.
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
SPRB Stock Hits 19-Month High Amid Trading Halts
Via Stocktwits
Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside
Via Stocktwits
Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Tuesday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Tuesday's session: gap up and gap down stocks
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Spruce Biosciences (SPRB) Stock Jumps 30% After Hours Following Red Hot Rally On Monday: Here's Why
Spruce Biosciences shares soared after the FDA granted Breakthrough Therapy Designation to its lead treatment for Sanfilippo Syndrome Type B. 
Via Benzinga
Why Spruce Biosciences Just Skyrocketed More Than 1,600%
The company is working on a treatment for a rare, genetic disease. 
Via Investor's Business Daily
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Spruce Biosciences Stock Is Soaring Today: Here's Why
Shares of Spruce Biosciences, Inc. (NASDAQ: SPRB) are surging Monday after the biotech company shared an important regulatory update about one of its therapy treatments. 
Via Benzinga
US Stocks Mixed; Dow Falls 100 Points
 
Via Benzinga
Topics Stocks
Wondering what's happening in today's pre-market session?
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
These stocks that are showing activity before the opening bell on Friday.
Wondering what's happening in Friday's pre-market session? Find an overview in this article. 
Via Chartmill
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Reverse Stock Split
From Spruce Biosciences, Inc.
Via Business Wire
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
From HMNC Holding GmbH
Via GlobeNewswire
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
From Spruce Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.